Mode
Text Size
Log in / Sign up
N/A N=30

Protamine in Cardiac Surgery and Haemostasis

Bleeding · Hemorrhage

Enrolled (actual)
30
Serious AEs
0.0%
Results posted
Nov 2015
Primary outcome: Primary: INTEM HEPTEM and FIBTEM Test of the ROTEM Coagulation Analyzer — 98; 117; 178; 253 seconds

Study Design & Population

Study type
Observational
Phase
N/A
Interventions
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Heart and Diabetes Center North-Rhine Westfalia
Primary completion
Mar 2012

Outcome Measures

OutcomeResultp-value
PRIMARY
INTEM HEPTEM and FIBTEM Test of the ROTEM Coagulation Analyzer
98; 117; 178; 253; 185; 267
PRIMARY
Rotem MCF Fibtem and MCF Intem
55; 57; 9; 13
SECONDARY
Transfusion of Blood Products and Coagulation Factors
76.7; 80; 20; 60; 20; 60
SECONDARY
12 h Postoperative Blood Loss
620; 723

Summary

Protamine is used after Cardiopulmonary Bypass (CPB) to reverse the anticoagulant effects of heparin and restore coagulation. Convincing evidence from in-vitro and in-vivo studies suggest that an overdose of protamine has anticoagulant effects which might lead to bleeding complications. Heparin levels usually decrease during cardiac surgery with CPB. Therefore, a protamine regimen based on the initial heparin dose before CPB might lead to overdose of protamine. In contrast, a protamine regimen based on the actual heparin concentration may avoid this condition. The investigators compare both regimens of protamine dosing in patients undergoing complex surgery with CPB and assess its effect on the amount of protamine given, markers of the coagulation system, utilization of blood products and perioperative blood loss.

Eligibility Criteria

Inclusion Criteria

  • Primary surgery
  • Preoperative hemoglobin value < 12 g/l
  • Preoperative platelet count < 200 c/µl
  • Patients with a body weight < 50 kg
  • No known defect of the coagulation system
  • Normal pre-operative ROTEM values of the INTEM and FIBTEM
  • Patients with unimpaired renal function (creatinine clearance < 30 ml/kg/min)

Exclusion Criteria

  • <18 years
  • No informed consent
  • Re-do surgery
  • Known defect of the coagulation system
  • Renal impairment
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01608971). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search